Please search for your last name

no photo
no photo
The University of Tokyo
Department of Bioengineering, Graduate School of Engineering
CNR
Institute of Crystallography
Irina Naletova, born March 8, 1980, graduated at the Bioorganic Chemistry Department of the Biology Department of Lomonosov Moscow State University in 2002. In 2006, she defended her PhD thesis at the Laboratory of Animal Cell Biochemistry of Lomonosov Moscow State University. From 2006 to 2012 she was a researcher at the laboratory of Animal Cell Biochemistry at Lomonosov MSU. In 2008-2009, she was teaching a practical course in General Biochemistry at Lomonosov Moscow State University. From 2012 to 2020 she was a postdoctoral researcher at the Department of Chemical Sciences and at the Department of Biotechnological and Biomedical Sciences, University of Catania, and from 2021 she is a temporary researcher at the Institute of Crystallography, National Research Council, Catania, Italy.
Alkahest
Data Science
Tibor Nanasi is a data scientist at Alkahest Inc and a scientific advisor at the RCNS, Budapest. He holds a PhD in theoretical medicine, an MSc in medical biotechnology and an MD. As a researcher, his main focus is the systems biology of aging and age related diseases, including the analysis of related changes in the blood plasma proteome.
no photo
University of Minnesota
Neuroscience
no photo
University of Florence
Department of experimental and clinical biomedical sciences
no photo
Tulane University School of Medicine
Neurosurgery
no photo
Icahn School of Medicine at Mount Sinai
Neurology
University of Barcelona
Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science
no photo
University of Alberta
Department of Medicine - Division of Neurology, Centre for Prions and Protein Folding Diseases,
Indiana University School of Medicine
Radiology and Imaging Sciences
My research expertise is in the areas of bioinformatics, imaging informatics, and medical informatics. I have become interested in integrating bio-, medical, and imaging informatics strategies in order to systematically explore associations between multi-omics such as genomics, transcriptomics, epigenomics, and metabolomics and brain pathology measured from multi-modal neuroimaging and fluid biomarkers in AD. I am currently the PI of an R01 grant award, the MPI of an U01 grant award, and the Co-I of several grants for integrating bio-, medical, and imaging informatics strategies to further identify genetic variation associated with multimodal biomarkers of AD risk and progression in whole genome sequencing (WGS) and other omics data as well as multimodal neuroimaging data.
University of Zurich
Institute for Regenerative Medicine
Ruiqing Ni Ruiqing Ni obtained her BSc in Pharmacy at Fudan University, China. She completed a Ph.D. in Medicine at Karolinska Institutet, Sweden. She is currently junior group leader at University of Zurich and ETH Zurich. Her research focuses on the development of positron emission tomography, optical imaging and magnetic resonance imaging bio-markers for diagnosis of Neurodegenerative diseases.
no photo
University College London
Genetics, Evolution and Environment
I am an ARUK Senior Research Fellow at the Institute of Healthy Ageing (IHA) in the Department of Genetics, Evolution and Environment (GEE). I obtained my PhD in 2002 from the laboratory of Paul Nurse at Cancer Research UK, investigating cell polarity in S. pombe. I then joined the laboratory of Daniel St Johnson at the Gurdon Institute in Cambridge as a Beit Memorial Fellow, looking at polarity during Drosophila oogenesis. I then took a career break to look after my two sons and completed a Master’s in Medical Ethics and Law at King’s College, London in 2009. In 2010 I joined the laboratory of Prof Linda Partridge at the Institute of Healthy Ageing (IHA) at UCL to work on Drosophila models of neurodegenerative diseases and then moved to Adrian Isaacs laboratory at the Dementia Research Centre at UCL. In 2019 I started my own group using Drosophila models to study dementia, in particular looking at the link between metabolism and neuronal cell death. In January 2019 I came back to the IHA to start my own group working on Drosophila models of dementia.
no photo
Helmholtz Zentrum München
Institute of Developmental Genetics
Stockholm University
Biochemistry and Biophysics
Dr. Nielsen earned her PhD researching the role of serine protease inhibitors in Alzheimer’s disease and dementia with Lewy bodies from Lund University in 2007. She received postdoctoral training at the VU Medical Center Amsterdam in the Netherlands where she studied amyloid-associated proteins like apolipoprotein E, and cellular amyloid-beta uptake in primary cultures of human astrocytes and microglia, and at Lund University where she headed biomarker discovery efforts in patients with Alzheimer’s and Parkinson’s disease. Following nearly four years as a research associate and assistant professor at the Mayo Clinic in FL USA, where she expanded on her interests mainly in apolipoprotein E, Dr. Nielsen accepted a faculty position at Stockholm University where she heads the Translational Neurodegeneration group as an associate professor of neurochemistry. Her main research focus comprises APOE4 phenotypic traits in humans, fluid levels of apolipoprotein E and their association with various pathology markers in mainly patients with Alzheimer’s disease, and the contribution of APOE4 to synucleinopathy. Dr. Nielsen's team is currently expanding on their studies into a potential role of the liver in the elevated risk of neurodegenerative disease in APOE4-carriers. Amongst several editorial assignments, Dr Nielsen is a senior editor of Molecular Neurodegeneration and the president of the newly established International Society for Molecular Neurodegeneration (ISMND).
Surrey and Borders Partnership NHS Foundation Trust
Abraham Cowley Unit
Ramin Nilforooshan is a Consultant Psychiatrist working in the National Health Service in UK and is a Visiting Professor at the University of Surrey. He is the Director for the Research & Development in his organisation; a role which involves safety and accuracy of clinical trials. His main research is on using IoT (Internet of Things) and AI (Artificial Intelligence) technology for dementia care. He is the Principal Investigator and Chief Investigator for number of national and international clinical trials and has considerable experience running clinical trials. He is currently clinical lead for the UK Dementia Research Institute, Care Research & Technology programme at Imperial College London.
no photo
AlzeCure Pharma AB
R&D
no photo
Sahlgrenska University Hospital / Mölndal
Department of psychiatry and neurochemistry
Karolinska Instituet
Department of Neurobiology, Care Sciences and Society (NVS) Division of Clinical Geriatrics
I am working on finding the molecular underpinnings of Alzheimer’s disease. My background is a PhD in molecular biotechnology from Uppsala University, Sweden. I did my postdoc at RIKEN Brain Science Institute, Japan. Since 2016 I am heading a research group at Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Sweden, where I am also vice/acting head of Division of Neurogeriatrics. Our research is focused on preclinical studies using animal models of Alzheimer’s in combination with clinical studies. The research is very much focused on protein homeostasis and the role of autophagy in amyloid β and tau metabolism, the two hallmarks of Alzheimer’s disease. This has led to pivotal findings showing that autophagy mediates the secretion of Alzheimer-causing amyloid β and that impaired autophagy during Alzheimer progression leads to neurodegeneration.